Hepatitis Clinical Trials

Showing 1601-1620 of 2,113 trials

Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort."

NCT02196064

To evaluate the incidence of grade 3 or 4 transaminase elevations or grade 4 total bilirubin elevations (hepatic toxicity) during the first 48 weeks of antiretroviral therapy with the combination of rilpivirine (25mg), tenofovir (245mg) and emtricitabine (200mg), in a single-tablet regimen (Eviplera®) in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected subjects.

Human Immunodeficiency Virus (HIV) Hepatitis C Virus (HCV) Coinfected Subjects

Fundación Pública Andaluza Progreso y Salud519 participantsStarted May 2014

Seville, Sevilla, Spain

UNKNOWN

A Hepatitis B With Hepatic Steatosis Study

NCT02392598

This is an epidemiologic study on effect of hepatic steatosis on prognosis and outcomes of patients with chronic hepatitis B.

Hepatitis B, ChronicHepatic Steatosis

Fatty Liver and Alcoholic Liver Disease Study Group, China3,000 participantsStarted Aug 2015

Zhangzhou, Fujian, China • Ji'nan, Shandong, China • Chengdu, Sichuan, China +4 more locations

COMPLETEDPhase 1

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

NCT01704846

The objective is to investigate the bioequivalence of 2 dose strengths of 40 mg and 120 mg BI 201335 NA soft gelatine capsules.

Hepatitis C

Boehringer Ingelheim60 participantsStarted Oct 2012

Sumida-ku,Tokyo, Japan

Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort."

A Hepatitis B With Hepatic Steatosis Study

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

Related Searches

Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)

A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Register of Telaprevir and Boceprevir in Routine Clinical Practice

Chronic Hepatitis C and Insulin Resistance

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients

Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

Directly Observed Hepatitis C Treatment in Methadone Clinics

Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C

Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy